Sagimet Q3 Loss Widens to $19.1M as AURORA Phase 3 Doses First Patient

Sagimet Biosciences Inc. (Nasdaq: SGMT) reported on 12 November 2026 a third-quarter net loss of $19.1 million, or $0.31 per share, as research and development spending jumped 68% to $16.3 million from $9.7 million a year earlier. The clinical-stage biopharmaceutical company said pro forma cash, cash equivalents and marketable securities stood at approximately $355.8 million at 30 September, after an October equity offering raised $115.0 million in gross proceeds. Sagimet's lead candidate, the oral FASN inhibitor denifanstat, is now in a U.S. registrational Phase 3 trial for moderate to severe acne.

Context — Why Sagimet's Q3 Loss Matters Now

Sagimet's loss widened even as revenue remained absent, which is normal for a company with no approved product. What changed is scale: research and development expense for the first nine months of 2026 reached $34.9 million, up from $32.3 million in the same 2025 period, while the quarterly figure nearly doubled. The company attributed the increase to advancing denifanstat and its pipeline.

The catalyst chain is clear. Sagimet's license partner Ascletis BioScience reported positive Phase 3 results for denifanstat in China, and a 52-week open-label extension showed sustained efficacy across all endpoints. Those results, presented at EADV 2026 and Fall Clinical Dermatology 2026, gave Sagimet the basis to launch its own U.S. registrational trial, AURORA, in October 2026.

General and administrative expense rose to $5.2 million from $4.6 million, a 14% increase. Total operating expenses were $21.6 million, against $14.3 million a year earlier. Other income of $2.4 million partly offset the operating loss.

Management frames the October financing as the event that extends the runway. David Happel, Sagimet's chief executive, said the company is positioned to fund its programs through mid-2029, covering the anticipated denifanstat Phase 3 readout and a potential NDA submission.

Data — What Sagimet's Q3 Numbers Show

The headline figure is the cash position. Reported cash, cash equivalents and marketable securities were $275.8 million at 30 September, including $27.5 million of investor funds received before the October offering closed. Pro forma for the $80.0 million in additional net proceeds received on 1 October, the balance rises to $355.8 million.

Metric	Q3 2026	Q3 2025
Research and development	$16.3M	$9.7M
General and administrative	$5.2M	$4.6M
Net loss	$19.1M	$12.9M
Net loss per share	$0.31	$0.40

Net loss per share fell despite the wider loss because weighted-average shares outstanding rose to 62.3 million from 32.5 million. For the nine months, net loss was $43.8 million, or $0.88 per share, versus $41.5 million, or $1.28 per share, a year earlier.

The balance sheet shows total assets of $282.1 million against $116.5 million at 31 December 2025. Stockholders' equity was $242.2 million. Current liabilities rose to $38.0 million from $5.1 million, reflecting obligations tied to the financing and operations.

Sagimet's AURORA trial plans to enroll approximately 800 U.S. patients aged 12 and older, including about 450 adolescents. Patients are randomized 2:1 to denifanstat 50 mg or placebo once daily for 12 weeks, with three co-primary endpoints assessed at week 12.

Analysis — What Sagimet's Pipeline Means for Healthcare Investors

Sagimet sits in a crowded dermatology space, but its mechanism is the differentiator. Denifanstat targets fatty acid synthase, a regulator of the lipogenesis pathway that is overactive in acne. The company said that if approved, denifanstat would be the first oral acne treatment with a novel mechanism approved by the FDA in more than 40 years.

The addressable market is large. Sagimet cited approximately 50 million Americans affected by acne annually, with about 10 million living with moderate to severe disease. That framing matters because it sets the commercial case investors will weigh against trial risk.

The limitation is timing and binary risk. AURORA topline data is expected in the second half of 2027, and the company has not disclosed efficacy data from its own U.S. trial. Positive China results from Ascletis are supportive but not a guarantee for U.S. registration.

Positioning reflects that split. The October raise brought in new capital at a $115.0 million gross size, suggesting institutional demand for the story. At the same time, the wider quarterly loss and rising current liabilities mean the equity is sensitive to any enrollment or safety signal before the readout.

Peers in inflammatory dermatology trade on pipeline optionality, and Sagimet's second asset, TVB-3567, adds another layer. A Phase 2 trial in moderate to severe acne is expected before the end of 2026.

Outlook — What to Watch for Sagimet

Three catalysts define the next twelve months. First, Sagimet expects to initiate a Phase 2 trial of TVB-3567 in moderate to severe acne before year-end 2026. Second, enrollment continues in the AURORA Phase 3 trial, with topline data anticipated in the second half of 2027. Third, the company is developing a topical FASN inhibitor formulation for acne, with no timeline disclosed.

The cash runway is the key level to watch. Sagimet said its pro forma balance is expected to fund operations through mid-2029, which covers the AURORA readout and a potential NDA submission. Any acceleration in spending or a slower enrollment pace would shorten that window.

Investors should also track the Ascletis relationship, since Sagimet's China partner holds the development and registration effort there. Positive updates from that program have historically preceded Sagimet's own trial milestones.

Frequently Asked Questions

What does Sagimet's Q3 2026 loss mean for retail investors?

The $19.1 million quarterly net loss is expected for a clinical-stage company with no product revenue. What matters is the cash position: $355.8 million pro forma, which the company says funds operations through mid-2029. That runway covers the AURORA Phase 3 readout and a potential NDA submission, reducing near-term financing risk.

What happens next for Sagimet's denifanstat acne program?

Sagimet plans to enroll approximately 800 patients in the U.S. AURORA Phase 3 trial, including about 450 adolescents. Topline data is expected in the second half of 2027. The trial has three co-primary endpoints assessed at week 12, and a subset of patients can enter a 40-week open-label extension.

Why did Sagimet's net loss per share fall while its net loss rose?

Net loss per share dropped to $0.31 from $0.40 because weighted-average shares outstanding nearly doubled to 62.3 million from 32.5 million. The October equity offering and prior financings increased the share count, spreading the larger net loss across more shares.

Bottom Line

Sagimet's $355.8 million pro forma cash funds denifanstat through a 2027 Phase 3 readout, making the AURORA data the binary event that defines the equity.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.